Complex Generics

Amphastar Pharmaceuticals (NASDAQ: AMPH) will participate in the 2025 Jefferies Global Healthcare Conference on June 5, featuring CFO Bill Peters and EVP Jacob Liawatidewi in a fireside chat. The company aims to highlight its growth strategy, including pipeline advancements in complex generics and proprietary drugs like BAQSIMI and Primatene MIST. With Q1 2025 R&D spending up 18%, analysts note its focus on innovative drug delivery systems, such as inhalation therapies, to disrupt traditional markets. The event, accessible via webcast, underscores Amphastar’s efforts to strengthen investor engagement and showcase manufacturing capabilities amid expanding portfolios in diabetes and emergency care.